ClinicalTrials.Veeva

Menu

Influence of COVID-19 on Vascular Endothelial Function (COVAS)

R

Radboud University Medical Center

Status

Unknown

Conditions

COVID
Vascular; Damage

Treatments

Diagnostic Test: Carotid Artery Reactivity Testing

Study type

Observational

Funder types

Other

Identifiers

NCT04468412
NL2020-6555

Details and patient eligibility

About

Rationale: Infection with severe acute respiratory syndrome coronavirus (SARS-CoV) 2 could result in endothelial dysfunction with increased risk of arterial thrombotic events by downregulating the expression of angiotensin converting enzyme 2 (ACE2). Endothelial function can be easily and non-invasively determined by carotid artery reactivity (CAR) testing.

Objective: To investigate the predictive value of endothelial dysfunction, measured by carotid artery reactivity testing, for 1-year cardiovascular events in patients with past COVID-19 infection.

Study design: A prospective observational longitudinal cohort study.

Study population: Patients recovered from confirmed infection with SARS-CoV2.

Main study parameters/endpoints: macrovascular endothelial function measured by carotid artery reactivity testing.

Enrollment

203 patients

Sex

All

Ages

16+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Confirmed SARS-CoV2 infection by polymerase chain reaction on nasopharyngeal swab, sputum or bronchoalveolar lavage.
  • At least 6 and no more than 20 weeks after resolution of COVID-19 related symptoms
  • ≥ 16 years old

Exclusion criteria

  • Recent (<3 months) angina pectoris, myocardial infarction, stroke, or heart failure
  • Raynaud syndrome, scleroderma, complex regional pain syndrome of the upper extremity or presence of arteriovenous fistula or open wounds on both the upper extremities.

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems